Cargando…
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186306/ https://www.ncbi.nlm.nih.gov/pubmed/35589114 http://dx.doi.org/10.1183/13993003.00388-2022 |
| _version_ | 1784724902528417792 |
|---|---|
| author | Guglielmetti, Lorenzo Günther, Gunar Leu, Claude Cirillo, Daniela Duarte, Raquel Garcia-Basteiro, Alberto L. Goletti, Delia Jankovic, Mateja Kuksa, Liga Maurer, Florian P. Méchaï, Frédéric Tiberi, Simon van Leth, Frank Veziris, Nicolas Lange, Christoph |
| author_facet | Guglielmetti, Lorenzo Günther, Gunar Leu, Claude Cirillo, Daniela Duarte, Raquel Garcia-Basteiro, Alberto L. Goletti, Delia Jankovic, Mateja Kuksa, Liga Maurer, Florian P. Méchaï, Frédéric Tiberi, Simon van Leth, Frank Veziris, Nicolas Lange, Christoph |
| author_sort | Guglielmetti, Lorenzo |
| collection | PubMed |
| description | Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh |
| format | Online Article Text |
| id | pubmed-9186306 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91863062022-06-13 Rifapentine access in Europe: growing concerns over key tuberculosis treatment component Guglielmetti, Lorenzo Günther, Gunar Leu, Claude Cirillo, Daniela Duarte, Raquel Garcia-Basteiro, Alberto L. Goletti, Delia Jankovic, Mateja Kuksa, Liga Maurer, Florian P. Méchaï, Frédéric Tiberi, Simon van Leth, Frank Veziris, Nicolas Lange, Christoph Eur Respir J Agora Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh European Respiratory Society 2022-05-19 /pmc/articles/PMC9186306/ /pubmed/35589114 http://dx.doi.org/10.1183/13993003.00388-2022 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
| spellingShingle | Agora Guglielmetti, Lorenzo Günther, Gunar Leu, Claude Cirillo, Daniela Duarte, Raquel Garcia-Basteiro, Alberto L. Goletti, Delia Jankovic, Mateja Kuksa, Liga Maurer, Florian P. Méchaï, Frédéric Tiberi, Simon van Leth, Frank Veziris, Nicolas Lange, Christoph Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title_full | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title_fullStr | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title_full_unstemmed | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title_short | Rifapentine access in Europe: growing concerns over key tuberculosis treatment component |
| title_sort | rifapentine access in europe: growing concerns over key tuberculosis treatment component |
| topic | Agora |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186306/ https://www.ncbi.nlm.nih.gov/pubmed/35589114 http://dx.doi.org/10.1183/13993003.00388-2022 |
| work_keys_str_mv | AT guglielmettilorenzo rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT gunthergunar rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT leuclaude rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT cirillodaniela rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT duarteraquel rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT garciabasteiroalbertol rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT golettidelia rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT jankovicmateja rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT kuksaliga rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT maurerflorianp rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT mechaifrederic rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT tiberisimon rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT vanlethfrank rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT vezirisnicolas rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent AT langechristoph rifapentineaccessineuropegrowingconcernsoverkeytuberculosistreatmentcomponent |